Evidence map›Paper›PMID 28770325›Full record

ReviewDiabetologia2017

Metformin use in pregnancy: promises and uncertainties.

Robert S Lindsay, Mary R Loeken

Open access · hybridAbstract readReview
In one paragraph

Review in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 3 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 122 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. [Management of hyperglycemia in pregnancy (Update 2026)].Wiener klinische Wochenschrift · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Metformin use in pregnancy: What about long-term effects in offspring?Acta obstetricia et gynecologica Scandinavica · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Immunomodulatory Effects of Metformin Treatment in Pregnant Women With PCOS.The Journal of clinical endocrinology and metabolism · 2023 · on this map
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Robert S LindsayInstitute of Cardiovascular and Medical Sciences, British Heart Foundation (BHF) Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK. robert.lindsay@glasgow.ac.uk.
Mary R LoekenSection on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, MA, USA.
Joslin Diabetes Center · USUniversity of Glasgow · GB

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI JEAN E. SCHAFFER · 1986 to 2026
$50.5M
Role of Slc2a2/Glut2 in Embryo and Stem Cell Metabolism, Self-Renewal, and Pathways Involved in Diabetic EmbryopathyR01DK104649 · NIDDK · JOSLIN DIABETES CENTER · PI LOEKEN, MARY R · 2015 to 2018
$2.1M
NIDDK NIH HHS P30 DK036836NIDDK NIH HHS R01 DK104649
6 · The paper itself

Abstract

Metformin has been prescribed in pregnancy for over 40 years; for much of this time, use has been limited both in numbers and geographically, and the evidence base has been confined to observational studies. In early years, perceived safety concerns and lack of availability of the drug in many countries acted as a barrier to use. More recently, RCTs have begun to examine the role of metformin in pregnancy in much-needed detail. However, this evidence base has been interpreted differently in different countries, leading to very wide variation in its current application in pregnancy. In this short review, we will discuss the history of metformin in pregnancy and highlight some of the key clinical trials. We will then consider some of the remaining controversies associated with metformin use in pregnancy, most important of these being the potential for long-term 'programming' effects on the fetus as a result of metformin being able to cross the placenta. We will also consider clinical situations where metformin might be avoided. Finally, we will discuss some future directions for this drug as it reaches its sixtieth anniversary.

Indexed as

FemaleHumansHypoglycemic AgentsMetforminPregnancyTeratogenesisHypoglycemic AgentsMetforminMetforminPregnancyReviewTeratogenesis

Identifiers

PMID28770325
PMCPMC5552827
OpenAlexW2739928654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.